MBX Biosciences Q1 net loss $23.9M; cash $240.8M; Phase 2 canvuparatide data due 3Q25

MBX Biosciences, Inc.

2025-Q1 EPS reported -$0.71

Net loss $23.9M (vs $12.3M YoY); R&D $22.4M (up 103% YoY) on MBX 4291 and canvuparatide trials.
Cash, cash equivalents & marketable securities $240.8M; expected to fund operations into mid-2027.
Phase 2 Avail topline results for canvuparatide in hypoparathyroidism expected in 3Q 2025.
IND submission for MBX 4291 (GLP-1/GIP co-agonist for obesity) on track for Q2 2025.
Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia expected to start H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.